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Emerging evidence of coding mutations in the
ubiquitin–proteasome system associated with
cerebellar ataxias
Sarah M Ronnebaum1, Cam Patterson2 and Jonathan C Schisler1,3
Cerebellar ataxia (CA) is a disorder associated with impairments in balance, coordination, and gait caused by degeneration of the
cerebellum. The mutations associated with CA affect functionally diverse genes; furthermore, the underlying genetic basis of a
given CA is unknown in many patients. Exome sequencing has emerged as a cost-effective technology to discover novel genetic
mutations, including autosomal recessive CA (ARCA). Five recent studies that describe how exome sequencing performed on a
diverse pool of ARCA patients revealed 14 unique mutations in STUB1, a gene that encodes carboxy terminus of Hsp70-interacting
protein (CHIP). CHIP mediates protein quality control through chaperone and ubiquitin ligase activities and is implicated in
alleviating proteotoxicity in several neurodegenerative diseases. However, these recent studies linking STUB1 mutations to various
forms of ataxia are the first indications that CHIP is directly involved in the progression of a human disease. Similar exome-
sequencing studies have revealed novel mutations in ubiquitin-related proteins associated with CA and other neurological
disorders. This review provides an overview of CA, describes the benefits and limitations of exome sequencing, outlines newly
discovered STUB1 mutations, and theorizes on how CHIP and other ubiquitin-related proteins function to prevent neurological
deterioration.
Human Genome Variation (2014) 1, 14018; doi:10.1038/hgv.2014.18; published online 23 October 2014
INTRODUCTION
‘Ataxia’ is a general term used to describe a loss of coordination.
Ataxia may be caused by a variety of diseases, including metabolic
disorders, vitamin deficiencies, peripheral neuropathy, cancer, or
brain injuries. However, ataxia may also be the result of progressive
deterioration of the cerebellum, which can be caused by a huge
variety of relatively rare genetic mutations in a family of disorders
termed ‘cerebellar ataxia’ (CA). In addition to alterations in
movement and balance, CA diseases can be accompanied by
impairments in speech, vision, and cognitive ability. The diseases
caused by CA mutations are inherited most commonly in
autosomal recessive CA (ARCA, estimated prevalence is 7 per
100,000) or autosomal dominant CA (ADCA, estimated prevalence
is 3 per 100,000) manners, in addition to less prevalent
mitochondrial or X-linked inheritance. Many forms of ADCAs are
caused by polyglutamine expansions within a protein-coding
region, whereas some ADCAs and most ARCAs are caused by
conventional mutations within the coding region (see Table 1). CAs
can also manifest as a secondary feature of neurological diseases
affecting the brain, such as Huntington disease, Parkinson disease,
cerebral palsy, and dentatorubral pallidoluysian atrophy. The age of
onset, prognosis, accompanying symptoms, and possible treatment
for a given CA depends on the underlying genetic mutation.
Until a few years ago, the rare occurrence and broad clinical
heterogeneity of CAs hindered the identification of underlying
genetic contributors. Prior to 2010, it had been estimated that the
genetic cause was unknown in ~ 40% of ADCA and ARCA cases.1
Identifying the genetic basis of CA is crucial for patients because
pinpointing the mutation can lead to information on treatments
to help manage the disease, identification of relatives currently at
risk of developing the disease, and accurate prenatal counseling
for family members. Although helping patients is the foremost
priority, genetic identification may also implicate novel biological
roles for ataxia-associated genes.
The advantages and limitations of using exome sequencing to
identify rare disease mutations
As whole-genome sequencing gradually becomes more accessible
due to lower costs and better data analysis methods, researchers
will continue to learn more about how noncoding regions of the
genome may regulate processes in a variety of diseases,2
including neurological diseases.3 However, although the exome
(the exon-associated portion of DNA that is transcribed into
mature mRNA) represents o1% of the entire genome, the current
inventory of disease-causing mutations appear to be dispropor-
tionately found in protein-coding regions.4 Exome sequencing has
emerged as a powerful technology to identify the genetic cause of
rare diseases like CAs, and is emblematic of how specialized
technology can be used universally within just a few years. First
used successfully to identify the basis of a rare disease in 2009,5
progressively lower costs and faster sequencing platforms have
promoted the mainstream use of exome sequencing over whole-
genome sequencing today.
Although exome sequencing currently has many advantages
over whole-genome sequencing, exome sequencing has technical
limitations beyond the inherent inability to detect mutations in
noncoding regions, including difficulty in demonstrating sufficient
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genetic coverage, a potential inadequacy in identifying chromo-
somal rearrangements, and difficulty in sequencing trinucleotide
repeats, such as the polyglutamine repeats, that characterize the
majority of known mutations in ADCA. Still, exome sequencing is
well suited for studying rare diseases caused by conventional
mutations, including ARCAs. There are several approaches a
clinical researcher can take when trying to identify the basis of an
ARCA. For example, an analysis of the exome profiles of unrelated
individuals presenting with the same syndrome may allow
researchers to pinpoint a disease-causing mutation. However, a
particular CA may be caused by mutations in different genes or by
different mutations within the same gene. A second approach to
identifying a disease-causing mutation is to sequence exomes
from affected and nonaffected individuals within a multigenera-
tional pedigree, although it is not always possible to obtain a
sufficient number of genetic samples. In either approach, a major
concern in studying autosomal recessive diseases through
sequencing is properly filtering single nucleotide polymorphisms
against control databases, such as dbSNP and 1000 Genomes
Project, since a ‘control’ population has a high likelihood of
Table 1. A summary of se veral CA subtypes, associated OMIM number, mutated genes, and function of the affected protein
Disease OMIM Gene Protein function
ADCAs
Repeat expansions in exons
DRPLA 125370 ATN1 Transcriptional corepressor
HD 143100 HTT Microtubule-mediated vesicle transport
HDL1 603218 PRNP Copper iron; microtubule binding
HDL2 606438 JPH3 Calcium-release channel activity
SCA1 164400 ATXN1 Nucleic acid binding
SCA17/HDL4 607136 TBP Transcription factor
SCA2 183090 ATXN2 RNA binding
SCA3 109150 ATXN3 Deubiquitinating enzyme
SCA6 183086 CACNA1A Voltage-gated calcium channel
SCA7 164500 ATXN7 Chromatin binding
Repeat expansions in noncoding regions
SCA10 603516 ATXN10 Unknown
SCA12 604326 PPP2R2B Protein phosphatase
SCA31 117210 BEAN1 Unknown
SCA36 614153 NOP56 Ribosomal RNA subunit biogenesis
SCA8 608768 ATXN8OS Noncoding gene
Missense, nonsense, insertion, or deletion mutations
ADCA-DN 604121 DNMT1 DNA methyltransferase
CANPMR 614756 CAMTA1 Transcriptional activator
Cortical myoclonus 614937 NOL3 RNA binding
Familiar dementia 176500 ITM2B ATP; beta amyloid binding
Gillespie syndrome 206700 PAX6 Transcription factor
SCA5 600224 SPTBN2 Cytoskeleton component
SCA11 604432 TTBK2 Protein kinase
SCA13 605259 KCNC3 Voltage-gated potassium channel
SCA14 605361 PRKCG Calcium-dependent protein kinase
SCA15/SCA16 606658 ITPR1 Ligand-gated calcium channel
SCA19/SCA22 607346 KCND3 Voltage-gated potassium channel
SCA23 610245 PDYN Neuropeptide hormone activity
SCA26 609306 EEF2 Translation factor
SCA27 609307 FGF14 Growth factor
SCA28 610246 AFG3L2 ATP-dependent protease
SCA35 613908 TGM6 Protein crosslinking; polyamine conjugation
ARCAs
AOA1 208920 APTX DNA repair
AOA2 606002 SETX DNA/RNA helicase
AOA3 615217 PIK3R5 PI3K regulation
Ataxia telangectasia 208900 ATM DNA damage-dependent protein kinase
Ataxia telangectasia-like disorder 604391 MRE11A DNA repair
Cayman 601238 ATCAY Unknown
Charlevoix-Saguenay 270550 SACS Cochaperone
Cockayne syndrome A 216400 ERCC8 DNA repair; ubiquitin ligase complex component
Cockayne syndrome B 133540 ERCC6 DNA repair
Coenzyme Q10 deficiency 607426 COQ2 Coenzyme Q biosynthesis
Friedreich ataxia 229300 FXN Iron homeostasis
Marinesco–Sjogren 248800 SIL1 Protein translocation/folding
MGA5 610198 DNAJC19 Protein translocation; cochaperone
PHARC 612674 ABHD12 Lipid hydrolysis
SCAN1 607250 TDP1 DNA repair
SCAR8 610743 SYNE1 Cytoskeleton
SCAR9 612016 CABC1 Kinase; coenzyme Q biosynthesis
Abbreviations: ADCAs, autosomal dominant cerebellar ataxias; ARCAs, autosomal recessive cerebellar ataxias; CA, cerebellar ataxia; DRPLA, dentatorubral
pallidoluysian atrophy; HD, Huntington disease; SCA, spinocerebellar ataxia.
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expressing a recessive mutation.6 In 2011, it was estimated that
exome sequencing could identify around 20,000 single nucleotide
polymorphisms per genetic sample, of which between 1 and 2%
were novel.7 As exome-sequencing data for control populations
becomes increasingly accessible,8 it will be easier to differentiate
single nucleotide polymorphismss from novel disease-causing
mutations.
Identification of a STUB1 mutation associated with Gordon Holmes
syndrome
Recently, exome sequencing was used to identify the probable
disease-causing mutation in two siblings diagnosed with Gordon
Holmes Syndrome (GHS; OMIM #212840), an ARCA characterized
by ataxia and hypogonadism.9 The exomes of the two affected
sisters and an unaffected male sibling were sequenced, and after
filtering for novel variants, a recessive inheritance pattern, location
within Identical By Decent regions, and predicted effects on
protein function, a single homozygous mutation within the coding
region of STUB1 met all criteria in the GHS patients.9 Carboxy
terminus of Hsp70-interacting protein (CHIP), the protein product
of STUB1, is a cochaperone and ubiquitin ligase that contains three
major protein domains: a tetratricopeptide repeat (TPR) domain
required for interaction with heat shock proteins (Hsp), a charged
domain that mediates CHIP’s dimerization and activity, and a
U-box domain that confers ubiquitin ligase activity (Figure 1a).
CHIP forms a homodimer and directly binds to Hsp70 and Hsp90
to aid in refolding substrates, or associates with ubiquitin-
conjugating enzymes to ubiquitinate substrates with canonical
or noncanonical chains.10–14 CHIP can also directly act as an
autonomous chaperone by promoting the proper folding and
activity of substrates.15,16 The homozygous GHS-associated STUB1
mutation found in this study (c.737C4T) results in the substitution
of methionine for threonine at residue 246 (p.T246M) and is
located within CHIP’s U-box domain (Figure 1a, Table 2).9 In vitro
studies indicated that the T246M mutation abolishes the ubiquitin
ligase activity of CHIP but does not disrupt the association
between CHIP and Hsp70.9
The GHS patients described in the above study exhibited an
unsteady gait that progressed to ataxia, cognitive impairments,
and inadequate sexual organ development accompanied by low
circulating levels of hormones required for reproductive develop-
ment (Table 2).9 Interestingly, CHIP− /− mice share these pheno-
types, although these deficiencies were initially overlooked due to
the more prominent findings of acute stress intolerance and
premature aging.11,17 However, on the basis of the data linking
CHIP to GHS, the neurological and reproductive phenotypes of
CHIP− /− mice were more closely examined, and impairments in
motor activity and spatial learning, cerebellar atrophy, and
Figure 1. (a) STUB1 genomic structure and corresponding CHIP protein domains are diagramed. The locations (arrows) of the various
mutations associated with ARCA and respective nucleic acid and amino acid changes are indicated in the inset table.9,8–21 Joined arrows
indicate a compound heterozygous mutation. (b) The protein structure of RNF216 (left) and OTUD4 (right) are shown with mutations
indicated with arrows and identified in the inset table.39,40 The domain abbreviations are: UTR, untranslated region; TPR, tetratricopeptide
repeat; CC, coiled coil; RING, really interesting new gene; IBR, in-between RING; OTU, ovarian tumor like.
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hypogonadism associated with low circulating hormone levels
were found.9 The combination of exome sequencing, in vitro data,
and recapitulation of the GHS phenotype in a mouse model
provide high confidence that CHIP, which was previously
unknown to have a direct role in any human disease, is essential
for cerebellar maintenance.
Identification of multiple STUB1 mutations associated with ARCA
Bolstering the evidence that loss-of-function mutations in CHIP are
causal to ARCA, a second group using exome sequencing reported
STUB1 mutations in six patients with ataxia and cerebellar
degeneration from three unrelated families.18 In one family, all
affected siblings demonstrated a homozygous mutation in STUB1,
whereas the patients in the remaining families demonstrated
compound heterozygous mutations (Figure 1a; Table 2), all of
which were predicted to substantially affect CHIP protein function.
The in silico predictions of altered protein function were
corroborated with data demonstrating that these various STUB1
mutations were associated with a reduction in the degradation of
a known CHIP substrate.18
A third group recently reported novel STUB1 mutations in two
siblings with ARCA who demonstrate cognitive deterioration.19
After ruling out polyglutamine expansions and mutations in over a
hundred ataxia-related genes, exome sequencing was employed
to determine whether a novel mutation was involved. Compound
heterozygous mutations in STUB1 were discovered in the two
patients; these mutations produced an amino-acid substitution in
the charged domain and a deletion in the U-box domain that
leads to a frameshift mutation, causing the insertion of eight new
amino acids and a premature stop codon (Figure 1a; Table 2).19
The two patients identified in this study developed symptoms in
early adulthood that consisted of gait and speech difficulties,
cognitive impairment, and cerebellar atrophy, although the
circulating levels of testosterone, luteinizing hormone, and follicle
stimulating hormone were normal, in contrast to the patients with
the T246M mutation.19
In addition, a fourth group performed exome sequencing on a
large population of ARCA patients that had been prescreened for
mutations in the most common ARCA diseases, and the
researchers discovered four novel STUB1 mutations in three
patients.20 Two unrelated patients harbored homozygous muta-
tions that led to amino-acid substitutions in the TPR domain and
in the U-box domain, whereas the other two patients were siblings
and expressed compound heterozygous mutations causing
amino-acid substitutions in the same amino acid within the TPR
domain (Figure 1a; Table 2).20 Interestingly, all patients in this
study had normal levels of estrogen and testosterone.20 The only
patient in this study demonstrating cognitive impairment
expressed the M240T mutation found within the U-box.20
Most recently, another group has reported on the case of ataxia
with myoclonus (muscle jerking), speech difficulties, balance
deterioration, and cognitive impairment in a patient harboring
compound heterozygous mutations in STUB1.21 One mutation
affected the first base of the intron between the fourth and fifth
exons, and the other affected the U-box domain.21 Together, these
studies demonstrate that mutations in CHIP are causative in
multiple ARCA patients from Asian9,18 and Caucasian19–21
ethnicities, and the cerebellar degeneration may or may not be
associated with cognitive impairment and hypogonadism.9,18–21
However, judging from the incidence of cognitive impairment
occurring in four out of five genetic signatures harboring
mutations that affect the U-box (Table 2), it is possible that
residual CHIP activity involving an intact TPR domain mitigates
clinical symptoms in some patients. At this point, the only
available animal model to study CHIP function is the mouse in
which the entire STUB1 gene has been deleted.11,17 Although it is
difficult to say at this time how mutations within the TRP, charged,
or U-box domains specifically affect the symptoms associated with
ARCA, the development of animal models with isolated domain
mutations may help identify how the bifunctional roles of CHIP
affect clinical pathologies.
The pathophysiological role of CHIP in neurodegenerative
diseases
Models of neurodegenerative diseases previously identified a
plausible role for CHIP in regulating neurological function;
however, not until the recent clinical studies has there been any
evidence that loss-of-function mutations in CHIP lead to severe CA
disease phenotypes in humans.9,18–21 CHIP associates with
numerous neuronal proteins. For example, CHIP is detected in
Lewy bodies;22 and CHIP recognizes and clears phosphorylated
tau23 and α-synuclein.22,24 CHIP suppresses toxicity caused by
LRRK225,26 and Huntingtin,27,28 and enhances the ubiquitin ligase
activity of wild-type Parkin.29 In a direct link to an ADCA, CHIP
mediates the degradation of a mutated polyglutamine-expanded
ataxin-1, a causative mutation in spinocerebellar ataxia 1 (SCA1).30
CHIP also participates in a negative feedback cycle with the E2
ubiquitin-conjugating enzyme E2W (Ube2w)and ataxin-3,31 a DUB
that targets noncanonical chains.32,33 Similar to ataxin-1, a
polyglutamine-expansion mutation in ataxin-3 is implicated in
the ADCA SCA3,34 and the severity of the pathological phenotype
of transgenic mice expressing the ataxin-3 polyglutamine-repeat
mutation is inversely proportional to CHIP copy number expres-
sion status.35 It should be noted that the role of CHIP in mitigating
mutant ataxin-3 toxicity in other ataxin-3 mutation models is
unclear.36 However, it is unlikely that the proteins listed above are
implicated in the pathology of the ARCA patients expressing
STUB1 mutations, as there were no additional mutations
Table 2. The affected protein domains, mutation type, and clinical phenotypes of the patients with STUB1 mutations as indicated in Figure 1a are
provided9,18–21
# Affected domain (s) Type Tendon reflex Cognitive impairment Hypogonadism Reference
1 TPR CHet Increased No No 20
2 TPR Hom Normal No No 20
3 TPR; charged CHet Normal No Not reported 18
4 Charged; U-box CHet Increased Severe No 19
5 Charged Hom Normal/increased Normal/mild Not reported 18
6 Intron; U-box CHet Increased Severe Not reported 21
7 Charged; U-box CHet Increased Normal Not reported 18
8 U-box Hom Normal Severe No 20
9 U-box Hom Normal/increased Severe Yes 9
‘CHet’ and ‘Hom’ refer to compound heterozygous and homozygous mutations, respectively.
Abbreviation: TPR, tetratricopeptide repeat.
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found.9,18–21 Supportive of the notion that loss of CHIP alone
directly causes ARCA is the observation that the early-onset of
disease and distinctive pathology of ARCA described in these
recent studies9,18–21 does not coincide with symptoms of SCA1,
SCA3, Parkinson, Alzheimer, or Huntington diseases. Together,
these data support a model where CHIP is involved in mediating
disease progression when a client protein is mutated; however, it
is now clear that a loss of CHIP function, caused by either
substitution or truncation mutations (Figure 1a), also leads to a
severe pathological consequence through an as yet undetermined
mechanism (summarized in Figure 2).
Mutations in the ubiquitin ligase RNF216 and the deubiquitianse
OTUD4 also associate with GHS
Of the 13 exon mutations in CHIP found in ARCA patients, 9 affect
either the charged linker region or the U-box domain (Figure 1a),
which are domains required for CHIP function and/or
dimerization.37,38 The identification of ataxia-associated mutations
that abolish CHIP’s ubiquitination activity,9,18–21 in addition to
recent reports of exome mutations in other proteins involved in
ubiquitination in other ataxia-related conditions,39,40 support
the distinct connection between neurological diseases and
defects in the ubiquitin–proteasome system (UPS) (reviewed in
references 41–44). A recent study of three siblings with GHS used
exome sequencing to find homozygous mutations in both the
ubiquitin ligase ring finger protein 216 (RNF216) and the
deubiquitinase OTU domain containing 4 (OTUD4), and sequen-
cing of RNF216 in six unrelated GHS patients demonstrated a
variety of heterozygous RNF216 mutations (Figure 1b).39 Impor-
tantly, the authors verified the involvement of RNF216 and OTUD4
in cerebellar function using zebrafish models demonstrating how
the depletion of either gene significantly increases the appearance
of cerebellar defects.39 Subsequently, an exome-sequencing study
consisting of several ataxia patients identified a unique RNF216
mutation in a GHS patient (Figure 1b).40 Unlike CHIP, targets of
RNF216 ubiquitin ligase activity are not well characterized.
However, overlap in the GHS phenotype associating with CHIP
and RNF216 mutations affords a unique comparative opportunity
to study CHIP and RNF216 activities that may provide the
molecular starting point to determine the mechanism by which
the loss of either E3 ligase could lead to GHS.
CA pathologies—converging at protein quality control?
The diverse etiology of the CA phenotype presents a challenge to
researchers. One common feature of some proteins involved in
ADCAs is polyglutamine expansion; otherwise, most ADCA
proteins are functionally unrelated (Table 1). As discussed above,
mutations in different genes such as STUB1 and RNF216 can give
rise to a similar phenotype. When the causal genes are
functionally related, it may provide some insight into the
pathophysiology. However, there are instances where causal
genes of a shared phenotype do not appear to be functionally
related; for example, Boucher–Neuhäuser Syndrome (OMIM
#215470) and GHS are both early-onset ARCAs accompanied by
hypogonadotropic hypogonadism. Although Boucher–Neuhäuser
Syndrome is characterized by chorioretinal dystrophy and GHS by
brisk reflex, both diseases can be caused by mutations in patatin-
like phospholipase domain containing 6 (PNPLA6),45 an enzyme
with little functional overlap with CHIP or RNF216. It is easy to
hypothesize that PNPLA6 is a substrate for either CHIP or RNF216,
but there has yet to be any data published to support this, and
currently it is unclear how PNPLA6 may intersect with the UPS.
However, in addition to the longstanding observation that
ubiquitin is present in aggregates that are hallmarks of several
neurodegenerative diseases,46 the use of exome sequencing in
recent studies demonstrated that multiple components of the UPS
are involved in CAs and other neurological and neurodegenerative
disorders. For example, ubiquitin carboxyl-terminal esterase L1
(UCHL1), a deubiquitinating enzyme that may also have ubiquitin
ligase activity, has previously been linked to Parkinson and
Alzheimer diseases.47,48 A homozygous missense mutation in
UCHL1 was found in three siblings with ataxia and severe
cerebellar atrophy,49 similar to mouse models in which UCHL1 is
mutated or deleted.50–52 Similarly, a mutation in ubiquitin protein
ligase E3 component N-recognin 4 (UBR4) was detected in a family
with episodic ataxia through exome sequencing.53 UPS compo-
nents have also been found to be mutated in some familial cases
of amyotrophic lateral sclerosis, including ubiquilin 2, a ubiquitin-
like protein,54,55 and valosin-containing protein (VCP), a ubiquitin
segregase.56 Exome sequencing also identified two different
mutations in an under-characterized protein, ubiquitin protein
ligase E3B (UBE3B), associated with Kaufman Oculocerebrofacial
Syndrome,57 whereas other UBE3B mutations result in an
intellectual deficiency disorder58 or associate with autism,59 again
demonstrating how distinct mutations in the same gene can give
rise to different phenotypes. In addition, some ARCAs are
attributed to mutations in genes involved in the UPS or in the
chaperoning of proteins (Table 1). One only has to look at the
myriad known CHIP substrates (Figure 2a) and phenotypes from
CHIP loss-of-function studies (Figure 2b) to appreciate the
neuronal demand for protein quality control. It is not surprising
that a collective theme is emerging, at least within a subset of CAs,
that clearly has a direct genetic link to the UPS and protein quality
control. Perhaps other known CA casual mutations in genes not
directly associated with the UPS cause a change in protein
stability, or perhaps participate in signaling networks that intersect
the UPS and protein quality control pathways in mechanisms not
previously characterized. Future efforts focusing on the molecular
characterization of newly identified coding mutations associated
with CAs should consider effects on protein stability and possible
implications to the UPS, as protein quality control is paramount in
maintaining neuronal cell homeostasis.
Figure 2. (a) The summary of the neurological proteins that serve as
CHIP substrates. (b) The effects of CHIP genetic depletion from
mouse models (left) and observed effects on humans with CHIP loss-
of-function mutations (right).
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CONCLUSIONS
As the global access to exome-sequencing technology and
analysis becomes increasingly available, there is tremendous
potential for successful identification of causal mutations of rare
diseases, such as CAs. The clinical identification of these
mutations, combined with basic and translational research
approaches, will foster new insights into human diseases and
uncover novel roles for genes and proteins that have direct links
to human diseases. We are confident that collaborative studies
combining clinical identification of mutations and basic research
models validating gene and protein function will uncover the
molecular mechanisms by which a single mutation leads to a
devastating condition and will foster therapies to help patients
with rare genetic diseases.
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